Go To Main content

::: Full time Faculty & Staff

Ya-Wen Lin Professor

Ya-Wen Lin Professor      
Ya-Wen Lin Ph.D.


2018-now Professor, Department of Microbiology and Immunology, National Defense Medical Center
2014-2017 Professor, Director, Department of Microbiology and Immunology, National Defense Medical Center
2013-2014 Professor, Department of Microbiology and Immunology, National Defense Medical Center
2010-2013 Associate Professor, Director, Department of Microbiology and Immunology, National Defense Medical Center
2009-2010 Associate Professor, Department of Microbiology and Immunology, National Defense Medical Center
2006-2009 Assistant Professor, Department of Microbiology and Immunology, National Defense Medical Center
2002-2006 Assistant Professor, Graduate Institute of Medical Sciences, National Defense Medical Center


Work Address No. 161, Sec 6, Min-Chuan E. Road, Taipei 114, Taiwan, R.O.C.
Work TEL 886-2-87923100 ext 18910
Work FAX 886-2-87917654
E-mail lyw@ndmctsgh.edu.tw or ndmc.yawen@msa.hinet.net


9/1986-6/1990 B.S. National Chung-Shing University, Taiwan
9/1990-6/1992 M.S. National Chung-Shing University, Taiwan
9/1995-1/2000 Ph.D. Department of Biochemistry, College of Medicine, National Taiwan University, Taiwan

Fields of study:

1. Epigenetics and cancer
2. Early diagnostic markers of cancer
3. Mechanism of heaptocarcinognesis

Honors and Awards

1. 2010, Excellent Award of SCI research articles, National Defense Medical Center
2. 2013-2017, High impact factor of SCI research articles, National Defense Medical Center
3. 2014, Excellent award of teachers, National Defense Medical Center, Ministry of National Defense
4. 2015-1017 Recruit and retain the special talents award for colleges and universities, National Defense Medical Center
5. Outstanding investigator award, Liver Disease Prevention and Treatment Research Foundation, 2016

Other Info


(*Corresponding authors)

1.         Wu JY, Shih YL, Lin SP, Hsieh TY, Lin YW*. YC-1 antagonizes Wnt/β-Catenin signaling through the EBP1 p42 isoform in hepatocellular carcinoma. Cancers (Basel). 2019 May; 11(5): 661. Published online doi: 10.3390/cancers11050661. *corresponding author.

2.         Chang SY, Kuo CC, Wu CC, Hsiao CW, Hu JM Hsu CH Chou YC, Shih YL*, Lin YW*. NKX6.1 hypermethylation predicts the outcome of stage II colorectal cancer patients undergoing chemotherapy. Genes Chromosomes Cancer., (2018, Jan) 57:268–277. *corresponding author.

3.         Chen YC, Kuo CC, Chian CF, Tzao C, Chang SY, Shih YL, Lin YW, Yu MH, Su HY. Knockdown of POLDIP2 suppresses tumor growth and invasion capacity and is linked to unfavorable transformation ability and metastatic feature in non small cell lung cancer. Exp Cell Res. 2018 Jul 1;368(1):42-49.  

4.         Shih YL, Kuo CC, Yan MD, Lin YW, Hsieh CB, Hsieh TY. (2016, Apr). Quantitative methylation analysis reveals distinct association between PAX6 methylation and clinical characteristics with different viral infections in hepatocellular carcinoma. Clin Epigenetics, 8:41. Published online 2016 Apr 22. doi: 10.1186/s13148-016-0208-3.

5.         Li HJ, Yu PN, Huang KY, Su HY, Hsiao TH, Chang CP, Yu MH, Lin YW*. (2016, Apr). NKX6.1 functions as a metastatic suppressor through epigenetic regulation of the epithelial-mesenchymal transition. Oncogene., 35(17):2266-78. *corresponding author.

6.         Chih-Chi Kuo, Ching-Yu Lin, Yu-Lueng Shih, Chung-Bao Hsieh, Pei-Yu Lin, Shuh-Bing Guan, Ming-Song Hsieh, Hung-Cheng Lai, Chien-Jen Chen and Ya-Wen Lin* Frequent methylation of HOXA9 gene in tumor tissues and plasma samples from human hepatocellular carcinomas. Clin Chem Lab Med 2014; 52. on line. (Corresponding author)

7.         Ya-Wen Lin, Yu-Lueng Shih, Gi-Shih Lien, Fat-Moon Suk, Chung-Bao Hsieh, and Ming-De Yan, “Promoter Methylation of SFRP3 Is Frequent in Hepatocellular Carcinoma,” Disease Markers, vol. 2014, Article ID 351863, 10 pages, 2014. doi:10.1155/2014/351863.

8.         Wen-Chi Lin, Ming-De Yan, Pei-Ning Yu, Hsin-Jung Li, Chih-Chi Kuo, Chia-Lin Hsu, Ya-Wen Lin* The role of Sp1 and EZH2 in the regulation of LMX1A in cervical cancer cells. Biochim Biophys Acta- Molecular Cell Research. 2013 Dec .1833(12):3206-3217. (Corresponding author)

9.         Ya-Wen Lin*, Chun-Ming Tsao; Pei-Ning Yu; Yu-Lueng Shih; Chia-Hsin Lin; Ming-De Yan*. SOX1 suppresses cell growth and invasion in cervical cancer. Gynecologic Oncology 2013 Oct,131(1):174-181.

10.     Yu, Pei-Ning, Yan, Ming-De, Lai, Hung-Cheng, Huang, Rui-Lan, Chou, Yu-Ching, Lin, Wen-Ch, Yeh, Li-Tzu, Lin Ya-Wen* Downregulation of miR-29 contributes to cisplatin resistance of ovarian cancer cells.  International Journal of Cancer 2014 Feb 1;134(3):542-51 (Corresponding author)

11.     Yang SM, Ka SM, Hua KF, Wu TH, Chuang YP, Lin YW, Yang SS, Lin SH, Chang JM, Chen A.  Antroquinonol mitigates accelerated and progressive IgA nephropathy model in mice via activating NrF2 pathway, and inhibiting T cells and NLRP3 inflammasome.. Free Radic Biol Med. (August) 2013, 61, 285-297.

12.     Tsao CM, Yan MD, Shih YL, Yu PN, Kuo CC, Lin WC, Li HJ, Lin YW* SOX1 functions as a tumor suppressor through antagonizing the WNT/beta-catenin signaling pathway in hepatocellular carcinoma. Hepatology. 2012 Dec;56(6):2277-87, *Corresponding author.

13.     Yu-Lueng Shih Chung-Bao Hsieh, Ming-De Yan, Chun-Ming Tsao, Tsai-Yuan Hsieh, Chang-Hsin Liu, Ya-Wen Lin* Frequent concomitant epigenetic silencing of SOX1 and SFRPs in human hepatocellular carcinoma.. Journal of Gastroenterology and Hepatology, 2013 Mar;28(3):551-559. *Corresponding author.

14.     Yo YT, Lin YW, Wang YC, Balch C, Huang RL, Chan MW, Sytwu HK, Chen CK, Chang CC, Nephew KP, Huang T, Yu MH, Lai HC. Growth inhibition of ovarian tumor-initiating cells by niclosamide. Mol Cancer Ther. 2012 Aug;11(8):1703-12. Epub 2012 May 10. (SCI)

15.     Su PH, Lin YW, Huang RL, Liao YP, Lee HY, Wang HC, Chao TK, Chen CK, Chan MW, Chu TY, Yu MH, Lai HC. Epigenetic silencing of PTPRR activates MAPK signaling, promotes metastasis and serves as a biomarker of invasive cervical cancer. Oncogene. 2012 Feb 13. doi: 10.1038/onc.2012.29. [Epub ahead of print]

16.     Hung-Cheng Lai, Ya-Wen Lin, Rui-Lan Huang, Ming-Tzeung Chung, Hui-Chen Wang, Yu-Ping Liao, Po-Hsuan Su, Yung-Liang Liu, and Mu-Hsien Yu. Quantitative DNA Methylation Analysis Detects Cervical Intraepithelial Neoplasms Type 3 and Worse  Cancer 2010 Sep15 116(18)4266-74. (SCI)

17.     Su HY, Lai HC, Lin YW, Liu CY, Chen CK, Chou YC, Lin SP, Lin WC, Lee HY, Yu MH. Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway.  Int J Cancer. 2010,127 (3) 555-567. (SCI)

18.     Chin-Yu Liu, Tai-Kuang Chao, Hsin-Yi Lee, Yu-Lueng Shih, Her-Young Su Tang-Yuan Chu, Mu-Hsien Yu, Ya-Wen Lin*, Hung-Cheng Lai* Characterization of LMX-1A as a metastasis suppressor in cervical cancer. Journal of Pathology 2009, 219(2):222-31. (SCI).

19.     Ya-Wen Lin*, Ming-De Yan, Yu-Lueng Shih, Chung-Bao Hsieh  The basal body gene, RPGRIP1L, is a candidate tumour suppressor gene in human hepatocellular carcinoma Eur J Cancer (2009) 45; 2041-2049.(SCI).

20.     Ya-Wen Lin* · Ming-Tzeung Chung · Hung-Cheng Lai · Ming De Yan · Yu-Leung Shih · Cheng-Chang Chang · Mu-Hsien Yu Methylation analysis of SFRP genes family in cervical adenocarcinoma. J Cancer Res Clin Oncol 2009 Dec;135(12):1665-74 (Epub 2009 Jun 10) (SCI).

21.     Ming-Tzeung Chung, Huey-Kang Sytwu, Ming-De Yan, Yu-Lueng Shih, Cheng-Chang Chang, Mu-Hsien Yu, Tang-Yuan Chu,  Hung-Cheng Lai*, and Ya-Wen Lin *  Promoter methylation of SFRPs gene family in cervical cancer. Gynecologic Oncology 2009, 112, 301–306 .These authors equally contributed to this work (SCI).

22.     Ming-Tzeung Chung, Hung-Cheng Lai,  Huey-Kang Sytwu, Ming-De Yan , Yu-Lueng Shih, Cheng-Chang Chang, Mu-Hsien Yu, Hang-Seng Liu, Da-Wei Chu, and Ya-Wen Lin* SFRP1 and SFRP2 suppress the transformation and invasion abilities of cervical cancer cells through Wnt signal pathway Gynecologic Oncology 2009, 112(3):646-53. (SCI)

23.     Her-Young Su, Hung-Cheng Lai, Ya-Wen Lin, Yu-Ching, Chou, Chin-Yu, Liu, Mu-Hsien, Yu An epigenetic marker for screening and prognostic prediction of ovarian cancer. Int J Cancer. 2009 124, 387–393. (SCI).

24.     Lin CT, Lai HC, Lee HY, Lin WH, Chang CC, Chu TY, Lin YW, Lee KD, Yu MH. Valproic acid resensitizes cisplatin-resistant ovarian cancer cells. Cancer Science 2008;99(6):1218-26. (SCI)

25.     Lai HC, Lin YW, Huang TH, Yan P, Huang RL, Wang HC, Liu J, Chan MW, Chu TY, Sun CA, Chang CC, Yu MH. Identification of novel DNA methylation markers in cervical cancer. Int J Cancer. 2008, 123(1):161-7. (SCI)

26.     Hung-Cheng Lai*&, Ya-Wen  Lin&, Cheng-Chang Chang, Hui-Chen  Wang, Ta-Wei  Chu, Mu-Hsien  Yu, , Tang-Yuan Chu  Hypermethylation of Two Consecutive Tumor Suppressor Genes, BLU and RASSF1A, Located at 3p21.3 in Cervical Neoplasias Gynecologic Oncology, 2007,104;629-635. &These authors equally contributed to this work.

27.     Yu-Lueng Shih1, Chung-Bao Hsieh, Hung-Cheng Lai, Ming-De Yan, Tsai-Yuan Hsieh, You-Chen Chao and Ya-Wen Lin* SFRP1 suppressed hepatoma cells growth through Wnt canonical signaling pathway Int. J. Cancer: 121, 1028–1035 (2007). (Correspondence)

28.     Yu-Lueng Shih, Rong-Yuan Shyu, Chung-Bao Hsieh, Hung-Cheng Lai, Kuo-Yu Liu, Tang-Yuan Chu, Ya-Wen Lin*  Promoter methylation of SFRP1 is frequent in hepatocellular carcinoma. Cancer 2006, 107(3);579-590. (correspondence).

29.     Ya-Wen Lin, Hung-Cheng Lai, Ching-Yu Lin, Jia-Yia Chiou, Hao-Ai Shui, Cheng-Chang Chang, Mu-Hsien Yu, Tang-Yuan Chu Plasma Proteomic Profiling for Detecting and Differentiating In-Situ and Invasive Carcinomas of the Uterine Cervix. International Journal of Gynecological Cancer  2006, 16:1216-1224.

30.     Ya-Wen Lin, Ching- Yu Lin , Hung-Cheng Lai , Jia-Yia Chiou, Cheng-Chang Chang, Mu-Hsien Yu, Tang-Yuan Chu Plasma proteomic pattern as biomarkers for ovarian cancer. International Journal of Gynecological Cancer 2006, Suppl 1:139-46.

  • Update Date:2021-03-22